Review: Pharmacokinetics of favipiravir in critically ill patients with COVID‐19

Home/Review: Pharmacokinetics of favipiravir in critically ill patients with COVID‐19

Review: Pharmacokinetics of favipiravir in critically ill patients with COVID‐19

Review: Pharmacokinetics of favipiravir in critically ill patients with COVID‐19

This small observational study found trough concentration in critically ill patients was much lower than that of healthy subjects in a previous clinical trial. This is cause for further pharmacokinetic research regarding optimal dosage and formulation for critically ill patients. 

  • The patients were administered 1600 mg of facipiravir twice daily on Day 1, followed by 600 mg twice daily from Day 2 to Day 5 (or more if needed). Trough levels were obtained
  • The clinical status after starting facipiravir was evaluated on Day 1–5, Day 7, and Day 14 by a seven-category ordinal scale
  • Seven patients were enrolled in this study. Forty‐nine blood samples were obtained these patients for the study
  • Although some improvement was observed in three patients with COVID-19 by Day 14, it is unclear how facipiravir influenced this improvement. (Sample size was very limited)
  • The facipiravir trough (after 8–12 h) concentrations of most samples (multiple samples for 5 of the 7 patients) were lower than the lower limit of quantification (1 µg/mL) and EC50 (9.7 µg/mL) against SARS‐CoV‐2 previously tested in vitro .
|2020-06-02T11:21:55-04:00June 1st, 2020|COVID-19 Literature|0 Comments

About the Author: Megan McHenry

Megan McHenry
Megan S. McHenry, MD, MS, FAAP is a pediatrician and an Assistant Professor of Pediatrics in the Ryan White Center for Pediatric Infectious Disease and Global Health at Indiana University School of Medicine. Dr. McHenry's research focuses on early childhood development in children living in resource-limited settings. This work is frequently aligned with community-engaged research and dissemination and implementation science frameworks. She primarily conducts research in collaboration with the Academic Model for Providing Access to Healthcare (AMPATH) Research Network in Kenya. Dr. McHenry currently has a career development award through the National Institutes of Health to develop a neurodevelopmental screening program for children born to HIV-infected mothers in Kenya. Dr. McHenry is also the Director of Pediatric Global Health Education and a co-Director of the Morris Green Physician-Scientist Development Program at Indiana University School of Medicine. In additional to global health lectures, she also educates residents and students on early childhood development, basic biostatistical techniques, research methodologies, and research ethics. She mentors multiple pediatric fellows, residents, and medical students interested in early childhood development within global contexts.

Get Involved with Indiana CTSI